About CStone
CStone Pharmaceuticals is a biopharmaceutical company devoted to the development of a new generation of innovative drugs. With its broad immuno-oncology pipeline, CStone is pursuing a development strategy focusing on combination therapy....
Research & Development
CStone is dedicated to building a leading end-to-end model for innovative drug development with a focus on clinical development.  
Pipeline
Cancer
IMMUNOTHERAPY
Immunotherapies activate or enhance the body’s immune system to overcome “immune-evasion” by identifying and attacking cancer cells; such therapies produce durable therapeutic benefit for a broad spectrum of cancer types with very mild toxicity, but they are only effective for a small subset of patients.
Pipeline
CStone Pipeline

CStone has a robust pipeline with 10+ innovative assets in oncology, one of the largest portfolio in China.
Pipeline
PD-L1
ABOUT CS1001
CS1001 (formerly codenamed WBP3155), independently developed and wholly owned by CStone Pharmaceuticals, is the first fully human, full-length innovative anti-PD-L1 drug candidate in China. Authorized by the U.S. based Ligand Corporation, CS1001 is also the first monoclonal antibody developed by the world leading OMT transgenic animal platform, which can generate fully human antibodies in one step.
RESEARCH & DEVELOPMENT
Media Center
PARTNER
JOIN US
COPYRIGHT © 2017 CSTONE PHARMACEUTICALS 沪ICP备17049547号  丨  Contact Us
  • 首页
  • 电话
  • 返回顶部